Clinical Trials

Access to Novel Treatments and Promising New Therapies

Research at Cancer Partners

We Are Committed to Innovation

Cancer Partners of Nebraska can now offer even more access to clinical trials, thanks to our membership in two major National Cancer Institute (NCI) research networks: Alliance is an affiliate of MD Anderson Cancer Center and ECOG-ACRIN Cancer Research Group.

  • Patient recruitment and enrollment in promising clinical trials is essential to the work that we do.
  • Cancer Partners is the first and only community oncology practice in Nebraska to become a member institution of the NCI clinical trials network.
  • The expanded clinical trials offered here bring academic-level treatment options to our local community.
  • We have access to over 300 new and innovative clinical trials for our patients.

Cancer Partners of Nebraska Human Research Protection Program

If you are not able to resolve your concerns with the study doctor or study staff, if you have a complaint, or if you have general questions about what it means to be in a research study, you can call the Cancer Partners of Nebraska Human Research Protection Program at (402) 420-7000, Ext. 202, or email

Clinical Trials

See What Clinical Trials Are Open Right Now

Most clinical trials at Cancer Partners are interventional studies, meaning patients are assigned to a treatment or other intervention and their outcomes are measured. See the full list below sorted by type of cancer. If you wish to discuss a specific trial, please discuss it with your oncologist or contact our Research Department at (402) 327-7363.

Breast Cancer

EA1181 – Her-2 positive Stage II-IIIa Breast Cancer (closing 10-19-23)

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy – (some cohorts closed, check with Research Department)

Learn More
NRG-BR007/DEBRA - Stage I, s/p lumpectomy


Learn More
NRG-BR008 - HER2+, Low risk Breast Cancer

A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)

Learn More

Central Nervous System Tumors (Brain and Spinal Cord) Cancer

A071702 - WHO Grade IV GBM (Glioblastoma)

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden

Learn More

Hematologic Cancer

CONNECT MDS/AML Myeloid Disorders

The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Learn More
S1918 (DLBCL age >75) Diffuse Large B Cell Lymphoma

A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements

Learn More
Connect Lymphoma

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Learn More
S1925 Asymptomatic High-Risk CLL/SLL

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed therapy with Venetoclax and Obinutzumab in Newly Diagnosed Asymptomatic High-Risk Patient with DLL/CLL: EVOLVE CLL/SLL Study.

Learn More
EAA181 (EQUATE) - MM, newly diagnosed, no transplant planned

A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma not Intended for Early Autologous Transplantation

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

(ON HOLD) Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with MM using minimal residual disease to direct therapy duration (DRAMMATIC STUDY).

Learn More

Gastrointestinal Cancer

A221805 – Stage II-III Colon Cancer Receiving Oxaliplatin (Early Stage Colon Cancer)

(Temp Closed) Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

Learn More

Thoracic Cancer

Unresectable Stage III or Metastatic (M1a) NSCLC - EF-36/Keynote B36

EF-36/ Keynote B36: A pilot, randomized, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first-line treatment of advanced or metastatic non-small cell lung cancer

Learn More
Stage IV EGFR Mutated NSCLC 1st line treatment - EA5182

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Learn More
ES-SCLC, 1st line - ASTRIDE

A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

A151216 - Resected Non-Small Cell Lung Cancer

Stage II-III Resected NSCLC – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Learn More
Stage II-III Resected NSCLC - A081801

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

Learn More
Stage IV, NSCLC - EF-36, Keynote B36

EF-36/ Keynote B36: A pilot, randomized, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first-line treatment of advanced or metastatic non-small cell lung cancer

A081801 - Stage II-III (Resected Non-Small Cell Lung Cancer)

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ACCIO)

Learn More
E4512 - Stage II-III ALK + Resected Non-Small Cell Lung Cancer

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Learn More
EA5181 - Unresectable Stage III Non-Small Cell Lung Cancer

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy of Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Learn More

Genitourinary Cancer

A031704 (PDIGREE) - Treatment Naïve Metastatic Renal Cell Carcinoma

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

Learn More
NRG-GU008 (INNOVATE) - Prostate Cancer, Treatment after Prostatectomy

Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy

Learn More
LA/mUC, 1st line, HER2+

SGNDV-001 -An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)



Stage II-IV, low grade serous NRG-GY019

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Solid Tumor


CASE - Cutaneous Squamous Cell Carcinoma

Cemiplimab Survivorship Epidemiology Study

Learn More
S2000 - Metastatic Melanoma

A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases

Learn More



Caris Biorepository (Matched Tumor)

Solid Tumor Matched Tissue and Blood Collection

Learn More
MT Group (MTG-022)

The list of available biomarker studies is always changing. Please contact Cancer Partners Research Department for the most current list.

To Top